Press release
Doxorubicin Market Set to Surge Significantly During 2016 – 2024 : Persistence Market Research
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). Anthracycline especially doxorubicin has been the mainstay of cancer treatment since many years. Doxorubicin also known as doxorubicin hydrochloride is an antibiotic belonging to class of medication known as anthracycline antibiotics, and is the first liposomal encapsulated anticancer drug to receive clinical approval and is used in the treatment of several types of carcinomas. Doxorubicin is produced by the soil fungus belonging to genus Streptomyces. The drug is used in combination with other drugs to treat cancers such as, breast, lung, bladder, stomach, ovarian, neuroblastoma, Hodgkin and non-Hodgkin lymphomas, and certain types of leukemia’s. It is less commonly used in treatment of squamous cell carcinomas of head and neck, cervix and vagina, carcinomas of testes and prostate. The drug kills the cancerous cells in several ways including intercalation between DNA pairs thereby preventing replication of cancer cells, DNA strand breakage and inhibition with enzyme topoisomerase II. Doxorubicin is marketed either in the powdered or in solution form and is administered intravenously every 21 to 28 days. However, the treatment depends upon the type of cancer being treated, the types of other drugs that are taken during the treatment and how well the body response to the medicine. The drug is sometimes given as a continuous infusion wherein the drug is infused slowly into the patient’s body.Global doxorubicin market is expected to witness upsurge in its revenue over the forecast period attributed to growing prevalence of cancer worldwide. WHO estimates that cancer prevalence is expected to increase at an estimated rate of 50% by 2050. Furthermore, increasing use of drug in the treatment of ovary cancer is further expected to increase the sales of the doxorubicin over the forecast period. The drug is also known to have high treatment efficacy in patients with AIDS-related Kaposi’s sarcoma after failure of prior systemic chemotherapy. However, conventional doxorubicin treatment imposes several side effects such as nausea and vomiting that may last 24–48 hours after treatment, hair loss, myelosuppression, loss of appetite, diarrhea, localized swelling etc. Therefore, the need for development of doxorubicin with liposomal formulation arose improving therapeutic index of conventional doxorubicin. This strategy resulted in preferential accumulation of doxorubicin within the cancerous cell in order to maximize the drug efficacy and minimize toxicity, thus fueling the doxorubicin market growth in the near future.
One of the most common and prevailing side effect of doxorubicin is cardiomyopathy with an estimated incidence of 4% at a dose of 500–550 mg/m², subsequently leading to congestive heart failure. The rate of cardiomyopathy reaches to 36% when the dose exceeds 600 mg/m². This may lead to introduction of drugs with lesser side effects replacing the doxorubicin in the future. However, ongoing shortages of the drug has also affected the revenues of the doxorubicin market contently.
Increasing prevalence of several cancer types have resulted in increasing usage of doxorubicin in clinical practice thus driving the revenues for the same. By formulation, the global market for doxorubicin has been classified into, lyophilized doxorubicin powder and doxorubicin solution
By cancer type, the global doxorubicin market is segmented into, breast cancer, prostate cancer, ovary cancer, lung cancer, bladder cancer, stomach cancer, leukemia and others. Breast cancer and prostate cancer segments are expected to account for maximum revenue share in global doxorubicin market over the forecasted period.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/12637
On the basis of distribution channel, the global doxorubicin market is segmented into, hospital pharmacies, retail pharmacies and e-commerce.
On the basis of regional presence, global doxorubicin market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America will continue to dominate the global doxorubicin market attributed to growing number of cancer epidemiology in the region. Furthermore, doxorubicin shortages in the past few years due to manufacturing issues have resulted in entry of increasing number of players in the market. This has substantially improved the revenue of global doxorubicin market in the near future. Asia Pacific is expected to be the fastest growing region in global doxorubicin market attributed to increasing prevalence of breast and lung cancer.
To View TOC of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/toc/12637
Some of the major players operating in global doxorubicin market are Pfizer Inc., Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., Meiji Seika Pharma Co., Ltd., Teva Pharmaceutical Industries Ltd., MicroBiopharm Japan Co., Ltd., and Synbias Pharma. Companies are involved in collaboration agreements for R&D in order to exploit maximum potential.
To view complete report @ http://www.persistencemarketresearch.com/market-research/doxorubicin-market.asp
About Us
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.
Contact
Persistence Market Research Pvt. Ltd
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
media@persistencemarketresearch.com
Web:www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Doxorubicin Market Set to Surge Significantly During 2016 – 2024 : Persistence Market Research here
News-ID: 585295 • Views: …
More Releases from Persistence Market Research

North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
Overview of the North America Wiring Devices Market
The North America wiring devices market is poised for steady growth over the forecast period, with its size estimated at US$ 18.96 billion in 2024, projected to reach US$ 26.46 billion by 2031, reflecting a CAGR of 4.9%. The market is witnessing substantial expansion due to increasing urbanization, a rising number of residential and commercial construction projects, and the adoption of energy-efficient and…

Global Forged Automotive Components Market Poised for Steady Growth, Projected t …
The global forged automotive components market is on a robust growth trajectory, currently valued at approximately US$ 50.3 billion in 2025 and forecasted to expand to US$ 70.7 billion by the end of 2032. This growth represents a compound annual growth rate (CAGR) of 5.0% over the coming decade, driven by increasing automotive production, technological advancements, and evolving consumer preferences toward durable, high-performance vehicle parts.
Forged automotive components are critical to…

Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ …
The global electric cargo bike market is set to experience substantial growth over the coming decade, with Persistence Market Research (PMR) forecasting a compound annual growth rate (CAGR) of 11.9% from 2023 through 2032. Valued at approximately US$ 800 million in 2021, the market is expected to surge to a projected valuation of US$ 2.14 billion by the end of 2032. Notably, electric cargo bikes accounted for 66.2% of the…

Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Drive …
The global bicycle bearings market is poised for significant expansion over the forecast period of 2025 to 2032, according to the latest report released by Persistence Market Research. Valued at approximately US$ 5.99 billion in 2024, the market is projected to reach US$ 6.35 billion by 2025 and further escalate to nearly US$ 9.86 billion by 2032. This growth trajectory reflects a compound annual growth rate (CAGR) of 6.5%, underscoring…
More Releases for Doxorubicin
Rising Prevalence Of Cancer Fuels Growth In Liposomal Doxorubicin Market: A Sign …
The Liposomal Doxorubicin Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Liposomal Doxorubicin Market Size and Projected Growth Rate?
The liposomal doxorubicin market has also shown strong growth in recent years. It is expected to grow from $1.23 billion in 2024 to $1.32…
Doxorubicin Market: Prospects for Long-Term Value & Growth
The "Global Doxorubicin" intelligence report, just published by USD Analytics, covers insurers' micro-level study of important market niches, product offers, and sales channels. In order to determine market size, potential, growth trends, and competitive environment, the Global Doxorubicin provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study featured Johnson…
Exploring the Doxorubicin Market: A Comprehensive Deep Dive
The Doxorubicin market has been on an impressive growth trajectory, largely propelled by the alarming surge in cancer cases across the globe. As of 2023, the market has already reached a substantial valuation of USD 1,218 million, and experts anticipate a promising future. Projections indicate a Compound Annual Growth Rate (CAGR) of 6.4% during the forecast period spanning from 2024 to 2032. This growth trajectory aims to achieve an astonishing…
Liposomal Doxorubicin Market - Powerful Delivery, Enhanced Outcomes: Empowering …
Newark, New Castle, USA - new report, titled Liposomal Doxorubicin Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liposomal Doxorubicin market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liposomal Doxorubicin market. The report offers an overview of the market, which…
Doxorubicin Market Value Projected to Expand by 2032
From 2022 to 2026, demand for doxorubicin is expected to rise at a 5.3% CAGR. The global doxorubicin market is currently valued at US$ 1.1 billion and is expected to reach US$ 1.3 billion by the end of 2026. Doxorubicin shipments in Japan and Canada are expected to rise at CAGRs of 3.9% and 5.3%, respectively, through 2026.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.factmr.com/connectus/sample?flag=S&rep_id=7303
Analysts aim to provide a…
Global Doxorubicin Market Insights, Forecast
Doxorubicin is a kind of antitumor antibiotics, can inhibit the synthesis of RNA and DNA, RNA in the strongest inhibitory effect. Doxorubicin has an effect on a wide variety of tumor, belongs to the cycle non-specific drug, have all sorts of growth cycle of tumor cells to kill.it's given by injection into a vein. The global Doxorubicin market is valued at 910 million US$ in 2018 and will reach 1410…